宫腔镜导管采集输卵管细胞学样本的多中心研究
这项前瞻性多中心单臂预试验纳入42例因盆腔可疑恶性肿瘤或BRCA突变预防性切除附件女性,用新型宫腔镜导管采集输卵管细胞,78条输卵管中65个开口被识别,61个插管成功,44例(68%)细胞学样本可评估,与输卵管病理一致率95%(42/44)。
要点
- 宫腔镜导管可获取68%可评估输卵管细胞学样本。
- 细胞学与输卵管病理一致率达95%(42/44)。
- 2例细胞学阳性但输卵管病理阴性者均为I期卵巢癌。
核心结论
- 该装置在68%的病例中获得可评估细胞学样本,且与输卵管组织病理学一致率高。
- 有必要进一步评估该装置在高危人群中检测恶性肿瘤的能力。
研究设计与样本
- 共入组50例患者,42例符合条件;40例完成宫腔镜检查,涉及78条输卵管。
- 使用FDA清除的新型宫腔镜导管采集输卵管细胞学样本,由对手术或病理结果不知情的病理学家评估。
主要发现
- 78条输卵管中识别65个开口(83%),其中61个(72%)成功插管,获得44份(68%)可评估细胞学样本。
- 44份样本中5份阳性(3份肿瘤性、2份恶性),39份阴性(34份良性、5份反应性/非典型)。
- 细胞学与输卵管组织病理学一致率为95%(42/44)。
- 2份不一致样本均为细胞学阳性而输卵管病理阴性,且均为I期卵巢癌伴恶性卵巢组织学。
临床怎么用
- 该装置可在多数病例中获取输卵管细胞学样本,或可用于高危人群的输卵管癌筛查评估。
- 细胞学结果需结合最终组织病理学综合判断,细胞学阳性而输卵管病理阴性时需警惕卵巢恶性肿瘤。
局限性
- 单臂预试验、样本量有限(42例符合条件),未设对照。
- 部分输卵管开口未能识别或插管失败,导致细胞学样本获取率有限(68%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the feasibility of a novel hysteroscopic catheter to collect fallopian tube cytologic samples and to correlate cytologic findings with histopathology. METHODS: This was a prospective, multicenter, single-arm pilot study. Women undergoing salpingo-oophorectomy for a pelvic mass suspicious for malignancy or for prevention of cancer for BRCA mutation carriers were recruited from 3 gynecologic oncology centers (October 2016-August 2017). Cytologic samples were collected from the fallopian tube using a novel FDA-cleared hysteroscopic catheter and evaluated by a pathologist blinded to surgical or pathologic findings. The correlation between cytologic results and final surgical pathology was assessed. RESULTS: Of the 50 patients enrolled, 42 were eligible. Hysteroscopies were completed in 40 patients with 78 fallopian tubes, of which 65 ostia (83%) were identified. Of these, 61 (72%) were successfully catheterized resulting in 44 (68%) cytology samples adequate for further evaluation: 5 were classified as positive (3 neoplastic and 2 malignant) and 39 as negative (34 benign and 5 reactive/atypical). A comparison of cytology results with fallopian tube histopathology showed a concordance rate of 95% (42/44). Of the two samples with discordant results, both had positive cytology but negative tubal pathology, and both were stage I ovarian cancers with malignant ovary histology. CONCLUSIONS: Deployment of the device yielded an evaluable cytologic sample in 68% of cases with a high rate of concordance with histopathology. Further evaluation of the device's ability to detect malignancy in high risk populations is warranted.
引用
- Powell CB, Littell RD, Landen CN, et al. Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study. Gynecol Oncol. 2020. PMID: 31918994. doi:10.1016/j.ygyno.2019.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。